Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 1631145

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1631145

Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids. Biologics), By Route Of Administration (Topical, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Atopic Dermatitis Drugs Market Growth & Trends:

The global atopic dermatitis drugs market size is expected to reach USD 29.88 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.02% from 2025 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.

A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.

Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.'s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.

An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.

The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.

Atopic Dermatitis Drugs Market Report Highlights:

  • The biologics segment dominated the market and accounted for 38.07% of the global revenue in 2024. The growth of the biologics segment is augmented by rising demand for biologics due to high efficacy, rising product approvals, and availability of a robust pipeline of biologic drugs for atopic dermatitis.
  • Topical segment dominated the market with a market share of 39.73% in 2024. The high prescription rates and affordability of medications, combined with the safety and efficacy of topical treatments, contribute significantly to their widespread use.
  • The hospital pharmacies segment held a considerable market share of 61.11% in 2024. Many patients with moderate to severe atopic dermatitis require prescription medications, which are often more readily available through hospital pharmacies.
  • The North America atopic dermatitis drugs market accounted for 45.12% share in 2024. This can be attributed to the high adoption rates of biologics and topical treatments.
Show more
Product Code: GVR-2-68038-546-5

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and Route of Administration outlook
    • 2.2.2. Route of administration and distribution channel outlook
  • 2.3. Competitive Insights

Chapter 3. Atopic Dermatitis Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of atopic dermatitis
      • 3.2.1.2. Rising awareness about disease
      • 3.2.1.3. Technological advancement
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations pertaining to drug approval
  • 3.3. Atopic Dermatitis Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Atopic Dermatitis Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Global Atopic Dermatitis Drugs Market: Drug Class Dashboard
  • 4.2. Global Atopic Dermatitis Drugs Market: Drug Class Movement Analysis
  • 4.3. Global Atopic Dermatitis Drugs Market By Drug Class, Revenue
  • 4.4. Corticosteroids
    • 4.4.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Calcineurin Inhibitors
    • 4.5.1. Calcineurin Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. PDE4 Inhibitors
    • 4.6.1. PDE4 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Biologics
    • 4.7.1. Biologics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Atopic Dermatitis Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Atopic Dermatitis Drugs Market: Route of Administration Dashboard
  • 5.2. Global Atopic Dermatitis Drugs Market: Route of Administration Movement Analysis
  • 5.3. Global Atopic Dermatitis Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 5.4. Topical
    • 5.4.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Parenteral
    • 5.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Oral
    • 5.6.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Atopic Dermatitis Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Atopic Dermatitis Drugs Market: Distribution Channel Dashboard
  • 6.2. Global Atopic Dermatitis Drugs Market: Distribution Channel Movement Analysis
  • 6.3. Global Atopic Dermatitis Drugs Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Other Pharmacies
    • 6.6.1. Online pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Atopic Dermatitis Drugs Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Pfizer Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Sanofi
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. AbbVie Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. GALDERMA LABORATORIES, L.P.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Eli Lilly and Company
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Regeneron Pharmaceuticals Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. LEO Pharma Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Otsuka Pharmaceutical Co., Ltd
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Novartis AG
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Incyte Corporation
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
Show more
Product Code: GVR-2-68038-546-5

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S. atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Canada atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Mexico atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Mexico atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 Europe atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Europe atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 Germany atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 21 Germany atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 UK atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 UK atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 UK atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 France atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 France atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 France atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Italy atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Italy atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Italy atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Spain atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Spain atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Spain atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Denmark atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Denmark atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Sweden atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 Norway atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 Norway atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Norway atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45 Aisa Pacific atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46 China atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 China atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 China atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Japan atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Japan atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Japan atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 India atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 53 India atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 54 India atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55 South Korea atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 South Korea atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 South Korea atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 Australia atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 Australia atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 Australia atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Thailand atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 62 Thailand atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63 Thailand atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64 Latin America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 65 Latin America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 66 Latin America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 67 Latin America atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 68 Brazil atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 69 Brazil atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 Argentina atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 72 Argentina atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Argentina atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 MEA atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 76 MEA atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 77 MEA atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 South Africa atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 79 South Africa atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 South Africa atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84 UAE atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 85 UAE atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 UAE atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Kuwait atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Kuwait atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Kuwait atopic dermatitis drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Atopic dermatitis drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Atopic dermatitis drugs market segment snapshot
  • Fig. 10 Atopic dermatitis drugs market competitive snapshot
  • Fig. 11 Atopic dermatitis drugs market driver impact
  • Fig. 12 Atopic Dermatitis Drugs market restraint impact
  • Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Value chain analysis
  • Fig. 16 Atopic dermatitis drugs market: Drug class outlook and key takeaways
  • Fig. 17 Atopic dermatitis drugs market: Drug class movement analysis
  • Fig. 18 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Calcineurin Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 PDE4 Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Atopic Dermatitis Drugs market: Route of administration outlook and key takeaways
  • Fig. 24 Atopic Dermatitis Drugs market: Route of administration movement analysis
  • Fig. 25 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Atopic Dermatitis Drugs market: Distribution channel outlook and key takeaways
  • Fig. 29 Atopic Dermatitis Drugs market: Distribution channel movement analysis
  • Fig. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Other pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Global Atopic Dermatitis Drugs market: Regional movement analysis
  • Fig. 34 Global Atopic Dermatitis Drugs market: Regional outlook and key takeaways
  • Fig. 35 Global Atopic Dermatitis Drugs market share and leading players
  • Fig. 36 North America, by country
  • Fig. 37 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. key country dynamics
  • Fig. 39 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Canada key country dynamics
  • Fig. 41 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Mexico key country dynamics
  • Fig. 43 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK key country dynamics
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 France key country dynamics
  • Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Italy key country dynamics
  • Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Spain key country dynamics
  • Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark key country dynamics
  • Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden key country dynamics
  • Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Norway key country dynamics
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 China key country dynamics
  • Fig. 63 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Japan key country dynamics
  • Fig. 65 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 India key country dynamics
  • Fig. 67 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Thailand key country dynamics
  • Fig. 69 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 South Korea key country dynamics
  • Fig. 71 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Australia key country dynamics
  • Fig. 73 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Brazil key country dynamics
  • Fig. 76 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Argentina key country dynamics
  • Fig. 78 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 South Africa key country dynamics
  • Fig. 81 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Saudi Arabia key country dynamics
  • Fig. 83 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 UAE key country dynamics
  • Fig. 85 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Kuwait key country dynamics
  • Fig. 87 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Market share Analysis of key market players, 2024
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!